TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00825370
Drug: IV opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
Study: NCT01708057
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8683 administered via inhalation
Study: NCT01708057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via inhalation
Study: NCT03866200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml once per day for 90 days
Study: NCT00843570
Drug: Nafarelin acetate, Oestradiol Valerate, Progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
Study: NCT03107195
Drug: Imaging Time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to be imaged at an additional time point.
Study: NCT00947349
Drug: BI 201335 NA low placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00947349
Drug: BI 201335 NA high placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00538681
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po, QD
Study: NCT01798303
Drug: LY2940094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01798303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00666562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01209715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
Study: NCT00004486
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01348737
Drug: AZD3839
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose
Study: NCT01348737
Drug: AZD3839 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose
Study: NCT01587950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Water
Study: NCT03490487
Drug: conventional antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study: NCT03490487
Drug: oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study: NCT01665937
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
Study: NCT00009737
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/m2 iv daily from day 1 to day 5 every 28 days.
Study: NCT00009737
Drug: Capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250mg/m2 po bid on days 1-14 every 21 days.
Study: NCT03878771
Drug: Dermovate cream in Orabase
Normalized name: benzocaine Topical Cream [Orabase]
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied on oral mucositis and /or ulcer 3 times per day
Study: NCT03426137
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
Study: NCT00376961
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 on day 1 of cycles 1-6.
Study: NCT00376961
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 on day 1 of cycles 1-6.
Study: NCT00618722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815111
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
Study: NCT00710333
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02829034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth twice per day for a total of 26 weeks
Study: NCT02031679
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
Study: NCT02031679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic AZD1981 10 mg tablet
Study: NCT01967043
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
Study: NCT03762967
Drug: Standard therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
Study: NCT01969721
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/dummy for blinding purposes
Study: NCT02493179
Drug: Serodase 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serodase 5mg two tablets three times per day
Study: NCT02493179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two tablets three times per day
Study: NCT04049994
Drug: Uro-Vaxom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
Study: NCT04049994
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT00896961
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110305
Drug: TMC278 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 25 mg tablet will be administered once daily.
Study: NCT00110305
Drug: TMC278 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
Study: NCT00110305
Drug: TMC278 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
Study: NCT00110305
Drug: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Study: NCT00142506
Drug: placebo tablets and questionaires
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Study: NCT00120328
Drug: SPP301
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03322800
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT03572088
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study: NCT00337389
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01517880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
Study: NCT02850848
Drug: (Baraclude 0.5mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04339868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl plus norepinephrine and/or epinephrine
Study: NCT02367846
Drug: Contraceptive Vaginal Ring (CVR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
Study: NCT01816503
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
Study: NCT03904927
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.
Study: NCT02241486
Drug: Sublingual Fentanyl Spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
Study: NCT00419796
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04315467
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A one-time infusion of SGM-101
Study: NCT04279197
Drug: Fuzheng Huayu Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Study: NCT04279197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Study: NCT01485874
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle
Study: NCT01830530
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets daily in the morning
Study: NCT02786069
Drug: Propionyl L-carnitine Hydrochloride
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
Study: NCT00809133
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose cohorts
Study: NCT01856101
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
Study: NCT00978302
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection at time of biopsy and again 24 h later
Study: NCT02595034
Drug: Clindamycin and Benzoyl Peroxide Gel 1%5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
Study: NCT02595034
Drug: BenzaClin® Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
Study: NCT02595034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT04177303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to placebo
Study: NCT04402047
Drug: Topical diclofenac sodium gel
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
Study: NCT01993719
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day X 2 days intravenous (IV)
Study: NCT01993719
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
Study: NCT01993719
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
Study: NCT04375631
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01103739
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
Study: NCT01797718
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/kg every 4 weeks for 6 months
Study: NCT02586805
Drug: DX-2930 - 300mg/4wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Study: NCT02586805
Drug: DX-2930 - 150mg/4wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Study: NCT02586805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 2 weeks by subcutaneous injection.
Study: NCT01569633
Drug: Metclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
Study: NCT01569633
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of erythromycin is 1 miligram per kilogram every eight hours
Study: NCT01569633
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of sugar water is 1 ml per 8 hours.
Study: NCT02906553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04321460
Drug: LRG-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
Study: NCT04321460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing placebo
Study: NCT00699192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule placebo to match valsartan orally once daily
Study: NCT01221857
Drug: NiCord®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
Study: NCT00224562
Drug: TNF-alpha antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03443830
Drug: Tyzivumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
Study: NCT02502981
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg orally once a day for 40 weeks
Study: NCT04241315
Drug: OTL38 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study: NCT01978119
Drug: FSC
Normalized name: Dofscort 3%-1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Study: NCT01978119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Study: NCT01422759
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-100 mg PO BID (X 12 weeks)
Study: NCT00426478
Drug: Valsartan plus Hydrochlorothiazide (80mg/12.5mg)
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03749226
Drug: Aztreonam lysine
Normalized name: aztreonam lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulization
Study: NCT02526368
Drug: Hyperpolarized 13C,15N2-urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00158184
Drug: Placebo 0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg placebo dose administered once a day, orally.
Study: NCT03467178
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy medication
Study: NCT03254173
Drug: Placebo oral tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets , half tablet daily before sleep for 8 weeks
Study: NCT03813030
Drug: Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion in clearance visit
Study: NCT00426348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01871792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
Study: NCT02351102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620020
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
Study: NCT00706628
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous doses every 4 weeks for 24 weeks
Study: NCT00452634
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40mg/QD, PO, daily, every 3 weeks
Study: NCT01911364
Drug: BDP/FF/GB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superiority over Tiotropium
Study: NCT01145560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00842933
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of corticosteroids 24 hours after cessation of vasopressors
Study: NCT00842933
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
Study: NCT00056199
Drug: EYE001
Approvals — FDA: no, EMA: no, PMDA: no